Chapter review

Fitzgerald PMHNP board review. ch04. Neuroscience. This is drive 2 of 5. When I say Pause. Answer. wait, then I will give the answer. New section. Dopamine Pathways and Schizophrenia. Topic. Pathways vs Symptoms Grouping. Bottom Line. - **Mesolimbic pathway**: Extends from the ventral tegmental area to the limbic system. Excessive dopamine tone in this pathway drives the positive symptoms of schizophrenia, including auditory hallucinations and delusions. Antipsychotic efficacy against psychosis requires D2 receptor blockade in this pathway. - **Mesocortical pathway**: Projects from the ventral tegmental area to the prefrontal cortex. Deficient dopamine in this pathway produces negative symptoms such as avolition, blunted affect, social withdrawal, and executive cognitive deficits. - **Nigrostriatal pathway**: Extends from the substantia nigra to the dorsal striatum to control voluntary and involuntary movement. Non-selective D2 receptor blockade by **first-generation antipsychotics** in this pathway causes extrapyramidal side effects, drug-induced parkinsonism, dystonia, and dyskinesia. - **Tuberoinfundibular pathway**: Projects from the arcuate nucleus of the hypothalamus to the anterior pituitary gland, where dopamine normally inhibits prolactin release. D2 blockade here, classically caused by **risperidone**, leads to hyperprolactinemia, galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction. - **First-generation vs. Second-generation antipsychotics**: **First-generation antipsychotics** bind D2 receptors tightly with slow dissociation, producing high rates of extrapyramidal adverse effects. **Second-generation antipsychotics** feature rapid D2 dissociation or serotonin 5-HT2A antagonism, resulting in lower rates of neurological adverse effects while maintaining equal clinical efficacy for positive symptoms. Signposts and Clinical Principles. - **First-line**: **Second-generation antipsychotics** are preferred as first-line pharmacotherapy over **first-generation antipsychotics** for schizophrenia because of their significantly lower risk of extrapyramidal symptoms, despite having equal overall efficacy for positive psychotic symptoms. - **Safety alert**: Unselective D2 blockade in the nigrostriatal pathway can precipitate acute dystonic reactions and neuroleptic malignant syndrome. Marked D2 blockade in the tuberoinfundibular pathway causes severe hyperprolactinemia, requiring baseline assessment and clinical monitoring for galactorrhea, menstrual disturbances, and long-term bone mineral density loss. - **Board trap**: Test-writers frequently try to trick candidates into choosing **second-generation antipsychotics** based on the misconception that they are more effective than **first-generation antipsychotics** for positive symptoms. The board standard is that overall efficacy for positive symptoms is equal between both generations; SGAs are chosen primarily for their reduced risk of extrapyramidal side effects due to rapid D2 receptor dissociation. High-Yield Concept Teaching: Pathways vs. Symptoms Grouping. Symptom-Governing Pathways. The **mesolimbic** and **mesocortical** pathways govern the core clinical features of schizophrenia and psychotic spectrum disorders: - The **mesolimbic pathway** originates in the ventral tegmental area and projects to subcortical limbic regions, including the nucleus accumbens and amygdala. Hyperactivity and excessive dopamine in this circuit generate positive psychotic symptoms, such as hallucinations, delusions, and thought disorganization. - The **mesocortical pathway** originates in the ventral tegmental area and projects directly to the prefrontal cortex. Hypoactivity and deficient dopamine in this circuit produce negative symptoms, such as blunted affect, alogia, apathy, and executive dysfunction. Side-Effect-Governing Pathways. The **nigrostriatal** and **tuberoinfundibular** pathways mediate iatrogenic adverse effects when D2 receptors are blocked by psychotropic medications: - The **nigrostriatal pathway** projects from the substantia nigra to the basal ganglia striatum, regulating motor planning and movement coordination. Blockade of D2 receptors in this pathway by antipsychotics reduces dopamine tone below the threshold required for smooth motor control, resulting in extrapyramidal symptoms, muscle rigidity, tremors, bradykinesia, acute dystonia, akathisia, and dyskinesias. - The **tuberoinfundibular pathway** connects the arcuate nucleus of the hypothalamus to the anterior pituitary gland. Dopamine acts as a tonic prolactin-inhibiting factor. Antipsychotic blockade of D2 receptors in this pathway removes prolactin suppression, resulting in hyperprolactinemia, galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction. Pharmacologic Modulation across Generations. Comparing **first-generation antipsychotics** and **second-generation antipsychotics**: - **First-generation antipsychotics** bind D2 receptors tightly throughout the central nervous system with slow dissociation rates. While effective at suppressing mesolimbic hyperdopaminergia, they unselectively block D2 receptors in the nigrostriatal and tuberoinfundibular pathways, generating significant extrapyramidal side effects and hyperprolactinemia. - **Second-generation antipsychotics** dissociate rapidly from D2 receptors or combine D2 antagonism with 5-HT2A antagonism. Serotonin 5-HT2A antagonism increases dopamine release in the nigrostriatal and mesocortical pathways, mitigating extrapyramidal symptoms and negative symptoms while maintaining therapeutic D2 blockade in the mesolimbic pathway. **Risperidone** retains potent D2 blockade in the tuberoinfundibular pathway, making galactorrhea a classic board stem clue for this medication. Fitzgerald Sample Test Questions. Question 5. Second-generation antipsychotics (SGAs) are preferred over first-generation antipsychotics primarily because of: A. Lower rate of adverse effects B. Slower dissociation from D2 receptors C. Less frequent dosing regimens D. Greater efficacy Pause. Answer. Keyed Answer: A. Why correct: **Second-generation antipsychotics** are clinically preferred over **first-generation antipsychotics** primarily because they carry a lower rate of neurological adverse effects, specifically extrapyramidal side effects. This advantage stems from their rapid dissociation from D2 receptors or dual 5-HT2A/D2 antagonism. Why each distractor fails: - Choice A is correct. - Choice B is wrong because SGAs feature more rapid dissociation from D2 receptors; slower dissociation is characteristic of FGAs and increases extrapyramidal symptom risk. - Choice C is wrong because dosing frequency is determined by individual drug half-life rather than drug generation, with both classes offering once-daily or long-acting formulations. - Choice D is wrong because national board standards emphasize that SGAs and FGAs possess equal overall clinical efficacy in treating positive psychotic symptoms. Question 7. The dopamine pathway that would be responsible for the positive symptoms of schizophrenia is: A. Mesolimbic dopamine pathway B. Nigrostriatal dopamine pathway C. Mesocortical dopamine pathway D. Tuberoinfundibular dopamine pathway Pause. Answer. Keyed Answer: A. Why correct: Excessive dopamine in the **mesolimbic dopamine pathway** drives the positive symptoms of schizophrenia, such as hallucinations, delusions, and thought disorganization. Antipsychotic efficacy against psychosis depends on D2 receptor blockade within this specific pathway. Why each distractor fails: - Choice A is correct. - Choice B is wrong because the **nigrostriatal dopamine pathway** regulates motor function, and its blockade by antipsychotics mediates extrapyramidal side effects rather than positive psychotic symptoms. - Choice C is wrong because the **mesocortical dopamine pathway** projects to the prefrontal cortex, where dopamine deficiency underlies negative symptoms and cognitive deficits. - Choice D is wrong because the **tuberoinfundibular dopamine pathway** regulates pituitary prolactin secretion, and its blockade results in hyperprolactinemia and galactorrhea. Question 8. Match the dopamine pathway with its appropriate function or symptoms: A. Mesolimbic dopamine pathway B. Nigrostriatal dopamine pathway C. Mesocortical dopamine pathway D. Tuberoinfundibular dopamine pathway Item 1: Prolactin regulation Pause. Answer. Keyed Answer: D. Why correct: The **tuberoinfundibular dopamine pathway** regulates prolactin secretion from the anterior pituitary gland, where dopamine acts as an inhibitory signal. Why each distractor fails: - Choice A is wrong because the mesolimbic pathway governs reward and positive psychotic symptoms. - Choice B is wrong because the nigrostriatal pathway governs motor control and movement disorders. - Choice C is wrong because the mesocortical pathway governs executive cognition and negative symptoms. Item 2: Voluntary and involuntary motor function Pause. Answer. Keyed Answer: B. Why correct: The **nigrostriatal dopamine pathway** connects the substantia nigra to the striatum to control voluntary and involuntary motor function. Why each distractor fails: - Choice A is wrong because the mesolimbic pathway controls emotional processing and positive symptoms. - Choice C is wrong because the mesocortical pathway controls prefrontal planning and cognitive processing. - Choice D is wrong because the tuberoinfundibular pathway controls neuroendocrine prolactin release. Item 3: Mood disorders and positive symptoms of psychosis Pause. Answer. Keyed Answer: A. Why correct: The **mesolimbic dopamine pathway** mediates reward processing, emotional regulation, and positive symptoms of schizophrenia like hallucinations. Why each distractor fails: - Choice B is wrong because the nigrostriatal pathway is involved in extrapyramidal motor regulation. - Choice C is wrong because the mesocortical pathway is involved in negative symptoms and executive functions. - Choice D is wrong because the tuberoinfundibular pathway is involved in endocrine regulation. Item 4: Cognition, planning, and executive behavior Pause. Answer. Keyed Answer: C. Why correct: The **mesocortical dopamine pathway** innervates the prefrontal cortex, regulating higher-order cognition, planning, and executive behavioral control. Why each distractor fails: - Choice A is wrong because the mesolimbic pathway projects to subcortical limbic regions governing positive symptoms. - Choice B is wrong because the nigrostriatal pathway projects to basal ganglia motor circuits. - Choice D is wrong because the tuberoinfundibular pathway projects to the pituitary neuroendocrine axis. Next. New section. Sample Questions: Neurotransmitters. Topic. Q1: Medications and NT Matching. Bottom Line. * **Benzodiazepines** enhance **GABA** inhibitory neurotransmission in the central nervous system to produce rapid anxiolytic effects. * **Fluoxetine** selectively blocks **serotonin** reuptake; because 90% of serotonin receptors reside in the gut, early gastrointestinal side effects like loose stools are common. * **Venlafaxine** dual-inhibits reuptake of **serotonin** and **norepinephrine**; elevated noradrenergic tone requires routine blood pressure monitoring. * **Methylphenidate** blocks reuptake of both **dopamine** and **norepinephrine**, increasing prefrontal cortex levels to treat **ADHD**. * **Bupropion** acts as a **dopamine** and **norepinephrine** reuptake inhibitor (**NDRI**), sparing serotonin to avoid sexual dysfunction and weight gain. * **Antipsychotics** block **dopamine** D2 receptors in the mesolimbic pathway; second-generation agents also antagonize 5-HT2A **serotonin** receptors to reduce extrapyramidal symptoms. * **Donepezil** inhibits acetylcholinesterase to prevent breakdown of **acetylcholine**, supporting cognitive function in **Alzheimer's disease**. High-Yield Neurotransmitter and Medication Mapping. Neurotransmitters regulate distinct central nervous system functions, and psychotropic medications modulate these pathways to treat psychiatric disorders. Over 50 neurotransmitters exist in the human brain, but national certification exams focus heavily on monoamines (dopamine, norepinephrine, serotonin, histamine) and amino acids (GABA, glutamate, acetylcholine). Primary Neurotransmitter Functions. * **GABA**: Primary inhibitory neurotransmitter in the central nervous system. Decreases neuronal excitability to reduce anxiety and muscle tension. * **Serotonin (5-HT)**: Calming neurotransmitter concentrated in the raphe nuclei. Precursor to melatonin. Regulates sleep, mood, impulse control, and anxiety. Approximately 90% of total body serotonin resides in the gastrointestinal tract. * **Norepinephrine**: Concentrated in the locus coeruleus. Regulates executive attention, alertness, and focus. Innervates the amygdala and prefrontal cortex. Excessive noradrenergic surge causes hypervigilance, autonomic arousal, and elevated blood pressure. * **Dopamine**: Concentrated in the substantia nigra, ventral tegmental area, and arcuate nucleus. Operates across four major brain pathways: mesolimbic (reward and psychosis), mesocortical (cognition and emotion), nigrostriatal (motor control), and tuberoinfundibular (prolactin regulation). Clinical Pearls and Exam Signposts. * **First-line**: **Selective serotonin reuptake inhibitors** (**SSRIs**) such as **fluoxetine** are first-line pharmacotherapy for **major depressive disorder**, **generalized anxiety disorder**, and **panic disorder** due to superior safety compared to older agents. * **Safety alert**: Routine blood pressure monitoring is required for medications that increase **norepinephrine**, including **SNRIs** (**venlafaxine**), **NDRIs** (**bupropion**), and psychostimulants (**methylphenidate**), as noradrenergic activity elevates resting vascular resistance. * **Board trap**: Prescribing an **SSRI** for a patient concerned about sexual dysfunction or weight gain is a classic exam error. **Bupropion** is the preferred alternative because its dual **dopamine** and **norepinephrine** reuptake inhibition completely spares serotonergic pathways. * **Safety alert**: Unselective D2 **dopamine** receptor blockade in the tuberoinfundibular pathway by antipsychotics, particularly **risperidone**, causes hyperprolactinemia resulting in galactorrhea, amenorrhea, and gynecomastia. * **Board trap**: Attributing negative symptoms of **schizophrenia** to mesolimbic dopamine excess is incorrect. Positive psychotic symptoms stem from **dopamine** hyperactivity in the mesolimbic pathway, whereas negative symptoms and cognitive deficits result from **dopamine** deficiency in the mesocortical pathway. Comparative Pharmacological Profiles. Monotherapy vs Dual-Action Mechanism * **SSRI (Fluoxetine)**: Selective **serotonin** reuptake inhibition. First-line for depression and anxiety. Key side effects include transient loose stools and persistent sexual dysfunction. * **SNRI (Venlafaxine)**: Dual **serotonin** and **norepinephrine** reuptake inhibition. Effective for depression and generalized anxiety. Requires blood pressure screening due to noradrenergic effects. * **NDRI (Bupropion)**: Dual **dopamine** and **norepinephrine** reuptake inhibition. Indicated for depression and smoking cessation; used off-label for **ADHD**. Free of serotonergic sexual side effects and weight gain. Contraindicated in seizure and eating disorders. First-Generation vs Second-Generation Antipsychotics * **First-Generation Antipsychotics**: Potent D2 **dopamine** receptor antagonists in the mesolimbic pathway. High risk of extrapyramidal side effects and tardive dyskinesia due to unselective D2 blockade in the nigrostriatal pathway. * **Second-Generation Antipsychotics**: Dual D2 **dopamine** and 5-HT2A **serotonin** receptor antagonists. Rapid dissociation from D2 receptors lowers extrapyramidal risk, though H1 **histamine** antagonism increases sedation and weight gain. Fitzgerald Chapter 4 Practice Bank: Question 1 Breakdown. Question 1. Match the medications with the involved neurotransmitters (more than one answer may apply). Available Choices: * A) GABA * B) Serotonin * C) Norepinephrine * D) Dopamine Item 1: Benzodiazepines. Pause. * **Answer**: A * **Why it is correct**: **Benzodiazepines** bind directly to **GABA** (gamma-aminobutyric acid) receptor complexes in the central nervous system, enhancing inhibitory chloride conductance to rapidly decrease neuronal firing and reduce anxiety. * **Why the other choices are wrong**: Option B (**serotonin**), Option C (**norepinephrine**), and Option D (**dopamine**) are incorrect because benzodiazepines do not primary target monoamine reuptake transporters or monoamine receptors. Item 2: Fluoxetine. Pause. * **Answer**: B * **Why it is correct**: **Fluoxetine** is a selective **serotonin** reuptake inhibitor (**SSRI**) that selectively blocks the presynaptic serotonin transporter pump, increasing synaptic serotonin concentrations in the brain. * **Why the other choices are wrong**: Option A (**GABA**) is incorrect because fluoxetine lacks direct GABAergic receptor activity; Option C (**norepinephrine**) and Option D (**dopamine**) are incorrect because fluoxetine has no significant noradrenergic or dopaminergic reuptake inhibition at therapeutic doses. Item 3: Venlafaxine. Pause. * **Answer**: B, C * **Why it is correct**: **Venlafaxine** is a **serotonin** and **norepinephrine** reuptake inhibitor (**SNRI**) that inhibits presynaptic reuptake transporters for both serotonin and norepinephrine, boosting dual synaptic levels. * **Why the other choices are wrong**: Option A (**GABA**) is incorrect because venlafaxine does not modulate GABA receptors; Option D (**dopamine**) is incorrect because venlafaxine lacks significant affinity for dopamine reuptake transporters at standard clinical dosages. Item 4: Methylphenidate. Pause. * **Answer**: C, D * **Why it is correct**: **Methylphenidate** is a central nervous system stimulant that blocks presynaptic reuptake transporters for both **norepinephrine** and **dopamine**, increasing synaptic concentrations in the prefrontal cortex to improve executive focus in **ADHD**. * **Why the other choices are wrong**: Option A (**GABA**) is incorrect as methylphenidate does not increase GABAergic inhibition; Option B (**serotonin**) is incorrect because methylphenidate does not meaningfully block serotonin reuptake. Item 5: Antipsychotics. Pause. * **Answer**: D (and B for second-generation agents) * **Why it is correct**: All **antipsychotics** antagonize **dopamine** D2 receptors in the mesolimbic pathway to treat positive psychotic symptoms. Second-generation antipsychotics additionally antagonize 5-HT2A **serotonin** receptors to modulate dopamine release and lower extrapyramidal risk. * **Why the other choices are wrong**: Option A (**GABA**) is incorrect because primary antipsychotics are not direct GABA agonists; Option C (**norepinephrine**) is incorrect because noradrenergic blockade is not the primary therapeutic mechanism for core antipsychotic efficacy. Item 6: Bupropion. Pause. * **Answer**: C, D * **Why it is correct**: **Bupropion** is a **norepinephrine** and **dopamine** reuptake inhibitor (**NDRI**) that selectively blocks reuptake pumps for dopamine and norepinephrine without affecting serotonin. * **Why the other choices are wrong**: Option A (**GABA**) is incorrect as bupropion has no direct GABA activity; Option B (**serotonin**) is incorrect because bupropion completely spares the serotonin reuptake pump, explaining why it does not cause serotonergic sexual dysfunction or weight gain. Next Study Step. Review Question 2 (Clinical Effects and Neurotransmitter Matching) in Fitzgerald Chapter 4 to solidify your mastery of clinical side effects, physical exam indicators, and pathway localization on board exam stems. Next. Topic. Q2: Clinical Effects and NTs. Bottom Line Summary. * **90 percent** of body serotonin resides in the gastrointestinal tract, causing early transient side effects like loose stools and nausea when starting SSRIs like **fluoxetine** or **sertraline**. * Serotonin dysregulation in the central nervous system leads to sexual dysfunction, including anorgasmia and decreased libido, affecting **30 to 50 percent** of patients on SSRI therapy. * Dopamine blockade in the tuberoinfundibular pathway disinhibits prolactin release, leading to hyperprolactinemia, galactorrhea, and amenorrhea, most notably with **risperidone**. * Dopamine blockade or neuronal degeneration in the nigrostriatal pathway produces dyskinesias and extrapyramidal motor symptoms, occurring at higher rates with first-generation antipsychotics. * Norepinephrine projections from the locus coeruleus regulate alertness, heart rate, and blood pressure, necessitating baseline and ongoing blood pressure checks with SNRIs like **venlafaxine** or stimulants. * Executive focus and concentration require dual noradrenergic and dopaminergic activity in the prefrontal cortex, targeted by stimulants like **methylphenidate** and NDRIs like **bupropion**. * Mesolimbic dopamine pathways running from the ventral tegmental area to the nucleus accumbens drive pleasure, reinforcement, and substance dependence. Sample Question Review: Clinical Effects and Neurotransmitters. Question 2 Sub-item 1: Loose Bowels After Starting Medication. Question: Match the clinical effect of loose bowels after starting a medication to the involved neurotransmitter. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: A. **Why it is correct:** Approximately **90 percent** of total body serotonin is concentrated in the gastrointestinal tract. Initiating serotonergic medications such as **fluoxetine** or **sertraline** stimulates enteric 5-HT receptors and increases gut motility, causing transient loose stools and abdominal cramping. **Why the other choices are wrong:** * B. Norepinephrine activates sympathetic pathways, which decreases gastrointestinal secretions and slows intestinal motility rather than causing loose stools. * C. Dopamine regulates reward, voluntary motor pathways, and prolactin secretion, without driving acute gastrointestinal hypermotility. **Safety alert:** Gastrointestinal side effects typically resolve within **1 to 2 weeks**. Persistent severe diarrhea accompanied by hyperreflexia, tremor, and autonomic instability indicates potential serotonin syndrome. **Board trap:** Do not mistake expected early gastrointestinal side effects of SSRIs for a drug allergy or treatment failure. **First-line:** Educate patients to take serotonergic medications with meals to reduce initial gastrointestinal distress. Question 2 Sub-item 2: Galactorrhea. Question: Match the clinical effect of galactorrhea to the involved neurotransmitter. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: C. **Why it is correct:** Dopamine acts as a prolactin-inhibiting factor in the tuberoinfundibular pathway. Antipsychotic blockade of dopamine D2 receptors disinhibits prolactin secretion from the anterior pituitary, leading to elevated prolactin levels, galactorrhea, gynecomastia, and amenorrhea. **Why the other choices are wrong:** * A. Serotonin signaling does not directly regulate tonic pituitary prolactin inhibition. * B. Norepinephrine regulates sympathetic arousal and attention but does not control pituitary prolactin release. **Safety alert:** Long-term hyperprolactinemia from dopamine D2 blockade can cause hypogonadism, menstrual cessation, and premature bone mineral density loss. **Board trap:** Assuming all second-generation antipsychotics carry equal risk for elevated prolactin is a mistake. **Risperidone** and **paliperidone** carry the highest risk of hyperprolactinemia among atypical agents. **First-line:** Obtain a serum prolactin level when a patient on D2-blocking antipsychotics presents with unexplained lactation or menstrual irregularities. Question 2 Sub-item 3: Focus and Concentration. Question: Match the clinical effect of enhancing focus and concentration to the involved neurotransmitters. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: B and C. **Why it is correct:** Prefrontal cortex cognitive processing depends on dual noradrenergic and dopaminergic transmission. Norepinephrine enhances signal clarity and alertness, while dopamine decreases background cognitive noise and enhances motivation. Psychostimulants like **methylphenidate** and **amphetamine** salts increase both synaptic norepinephrine and dopamine to improve ADHD symptoms. **Why the other choice is wrong:** * A. Serotonin regulates mood stability, sleep cycles, and impulse inhibition rather than targeted prefrontal signal-to-noise ratio and executive focus. **Safety alert:** Enhancing central dopamine and norepinephrine with stimulants can precipitate hypomania, exacerbate active psychosis, or increase cardiovascular strain. **Board trap:** Attributing executive focus solely to dopamine is a common board error. Optimal prefrontal attention networks require both norepinephrine and dopamine signaling. **First-line:** **Atomoxetine**, a selective norepinephrine reuptake inhibitor, is a primary non-stimulant choice for ADHD when psychostimulants are contraindicated due to active substance use disorder. Question 2 Sub-item 4: Elevated Blood Pressure. Question: Match the clinical effect of elevated blood pressure to the involved neurotransmitter. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: B. **Why it is correct:** Norepinephrine projections from the locus coeruleus stimulate central and peripheral adrenergic receptors, increasing cardiac contractility, heart rate, and systemic vascular resistance. **Why the other choices are wrong:** * A. Serotonin primarily impacts mood and gut motility without directly elevating systemic arterial tone at standard therapeutic levels. * C. Central dopamine D2 receptor blockade does not directly produce sustained systemic hypertension. **Safety alert:** Always check baseline blood pressure before initiating noradrenergic agents like **venlafaxine**, **bupropion**, or stimulants, and recheck at follow-up visits. **Board trap:** Prescribing high doses of **venlafaxine** without monitoring blood pressure is a tested distractor. Venlafaxine displays dose-dependent noradrenergic activity that can elevate diastolic blood pressure. **First-line:** Measure blood pressure at every clinical encounter when titrating SNRIs, NDRIs, or psychostimulants. Question 2 Sub-item 5: Sexual Dysfunction After Starting Medication. Question: Match the clinical effect of post-medication sexual dysfunction to the involved neurotransmitter. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: A. **Why it is correct:** Serotonergic stimulation of 5-HT2 and 5-HT3 receptors inhibits spinal sexual reflexes, diminishing libido, delaying orgasm, or causing complete anorgasmia in up to **30 to 50 percent** of patients taking SSRIs. **Why the other choices are wrong:** * B. Norepinephrine elevation increases energy and vigilance without directly causing serotonergic anorgasmia or delayed ejaculation. * C. Dopamine enhances sexual motivation and drive. Dopamine agonists and dopamine-enhancing drugs are used to treat SSRI-induced sexual side effects. **Safety alert:** Antidepressant-induced sexual dysfunction is one of the most common causes of abrupt medication non-adherence. **Board trap:** Expecting SSRI-induced sexual dysfunction to spontaneously resolve over time is incorrect. Unlike early nausea, sexual side effects generally persist throughout the duration of treatment. **First-line:** Switch to or augment with **bupropion**, a norepinephrine-dopamine reuptake inhibitor, to reverse serotonergic sexual dysfunction. Question 2 Sub-item 6: Dyskinesias. Question: Match the clinical effect of dyskinesias to the involved neurotransmitter. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: C. **Why it is correct:** Motor dyskinesias and extrapyramidal symptoms stem from dopamine D2 receptor blockade or neuronal degeneration in the nigrostriatal pathway, which coordinates smooth voluntary motor movement. **Why the other choices are wrong:** * A. Serotonin neurons originating in the raphe nuclei do not primary modulate extrapyramidal motor tracts in the basal ganglia. * B. Norepinephrine pathways regulate autonomic fight-or-flight responses rather than nigrostriatal motor control. **Safety alert:** Persistent dopamine D2 blockade in the nigrostriatal tract can cause irreversible tardive dyskinesia, marked by involuntary choreoathetoid movements of the tongue, lips, and face. **Board trap:** First-generation antipsychotics carry a significantly higher risk of nigrostriatal D2 blockade dyskinesias than second-generation antipsychotics, which dissociate more rapidly from D2 receptors. **First-line:** Perform regular involuntary movement evaluations using the AIMS scale and transition to a second-generation antipsychotic with rapid D2 dissociation if motor side effects emerge. Question 2 Sub-item 7: Substance Dependence. Question: Match the clinical effect of substance dependence to the involved neurotransmitter. * A. Serotonin * B. Norepinephrine * C. Dopamine Pause. Answer: C. **Why it is correct:** Dopamine release in the mesolimbic pathway, connecting the ventral tegmental area to the nucleus accumbens, mediates reward, euphoria, and behavioral reinforcement in substance use disorders. **Why the other choices are wrong:** * A. Serotonin regulates mood and impulse control but does not serve as the primary chemical signal in the mesolimbic reward center. * B. Norepinephrine drives autonomic hyperarousal during substance withdrawal but does not directly mediate core reward euphoria. **Safety alert:** Drugs of abuse trigger surges of dopamine in the mesolimbic pathway, leading to receptor down-regulation, tolerance, and compulsive drug-seeking behavior. **Board trap:** Confusing the mesolimbic pathway with the mesocortical pathway is a frequent exam error. The mesolimbic pathway drives reward and positive psychotic symptoms, while the mesocortical pathway governs cognition and negative psychotic symptoms. **First-line:** Combine evidence-based psychotherapies with FDA-approved craving-reduction medications to stabilize mesolimbic signaling in substance use recovery. Next Study Step. Proceed to **Fitzgerald Chapter 4: Sample Questions on Dopamine Pathways** to master how mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways dictate both psychotic symptoms and antipsychotic adverse effects on board exams. Next. Topic. Q3: Bupropion Mechanism. Bottom Line Summary. * **Bupropion mechanism**: Selective Norepinephrine-Dopamine Reuptake Inhibitor (**NDRI**), blocking presynaptic reuptake transporters for both **dopamine** and **norepinephrine**, elevating synaptic levels of both catecholamines [1-3]. * **Indications and off-label usage**: **First-line** agent for **major depressive disorder** (MDD) and **seasonal affective disorder**, FDA-approved for **smoking cessation** under the trade name Zyban, and prescribed off-label for **ADHD** due to its prefrontal cortex noradrenergic and dopaminergic enhancement [1, 3]. * **Sexual and weight profile**: Completely spares the **serotonin** system (no 5-HT2 or 5-HT3 activation), making it a preferred **first-line** alternative or augmenting agent when patients develop **SSRI-induced sexual dysfunction** or unwanted weight gain [1, 4]. * **Safety alert**: Lowers the **seizure threshold**; absolutely contraindicated in patients with a history of **seizures**, current or past **anorexia nervosa** or **bulimia nervosa**, or those undergoing abrupt withdrawal from **alcohol** or **benzodiazepines** [1, 4]. * **Vascular monitoring**: Noradrenergic reuptake inhibition increases synaptic **norepinephrine**, which can elevate **blood pressure** and **heart rate**, requiring baseline and periodic blood pressure checks [4, 5]. * **MAOI washout timeline**: Requires a strict **14-day washout period** when switching to or from a **monoamine oxidase inhibitor** (MAOI) to avoid triggering a lethal **hypertensive crisis**. High-Yield Concept and Neurobiology. Bupropion (Wellbutrin). * **What it is**: A dual **norepinephrine** and **dopamine** reuptake inhibitor (**NDRI**) that increases catecholamine concentration in the synaptic cleft without affecting serotonin [1-3]. * **Why boards care**: Highly testable as the primary non-serotonergic antidepressant choice to avoid sexual side effects, sedation, and weight gain, and as a classic drug safety item regarding seizure contraindications [1, 3, 4]. * **Must know criteria and features**: Spares **serotonin** receptors entirely [1, 2]. Enhances reward pathways (**mesolimbic dopamine**) and attentional circuits (**prefrontal cortex norepinephrine**) [1, 3, 6, 7]. * **Typical board clue**: A patient with **major depressive disorder** who achieves partial remission on an SSRI but complains of severe **anhedonia**, **fatigue**, or **sexual dysfunction**, or a depressed patient who wants to quit **smoking** [1, 3, 4]. * **First-line approach**: **First-line** for unipolar depression, particularly when weight gain, fatigue, or sexual dysfunction on other agents is a major concern [1, 4]. * **Safety alert**: Never prescribe bupropion to patients with **eating disorders** (**bulimia** or **anorexia**) or active **seizure disorders** [1, 4]. Electrolyte purging or starvation combined with bupropion markedly lowers the seizure threshold [1, 4]. * **Board trap**: Choosing bupropion for a depressed patient with severe unmanaged **panic disorder** or acute **insomnia**. The noradrenergic drive of bupropion can exacerbate **hyperarousal**, **anxiety**, and **sleep onset insomnia** if not properly timed or managed [4, 8]. Compare and Distinguish. Bupropion vs. SSRIs (e.g., Fluoxetine, Sertraline) * **Think**: NDRI (dopamine and norepinephrine) vs. Selective Serotonin Reuptake Inhibitor [1, 2, 9]. * **Priority**: Choose bupropion when preserving sexual function or avoiding weight gain is essential [1, 4]. Choose SSRIs as **first-line** for primary anxiety disorders, OCD, or PTSD [1, 9]. * **Boards are testing**: Recognizing that bupropion has zero serotonergic activity, eliminating risks of **diarrhea**, **sexual dysfunction**, or **serotonin syndrome** [1, 4, 10]. Bupropion vs. SNRIs (e.g., Venlafaxine, Duloxetine) * **Think**: NDRI (dopamine and norepinephrine) vs. SNRI (serotonin and norepinephrine) [1, 2, 11]. * **Priority**: Both classes boost **norepinephrine** and require **blood pressure** monitoring [4, 5]. SNRIs block serotonin reuptake, retaining serotonergic side effects and withdrawal symptoms [4, 11]. Bupropion blocks dopamine and norepinephrine with no serotonin effect [1-3]. * **Boards are testing**: Identifying that only bupropion carries the strict contraindication for **eating disorders** and **seizures** [1, 4]. Sample Board Questions. Question 3. Question: The mechanism of action of bupropion is as a selective reuptake inhibitor of: * A. Serotonin and dopamine * B. Norepinephrine * C. Dopamine and norepinephrine * D. Serotonin and norepinephrine Pause. Answer: C [2, 3]. Quick Answer. Bupropion is a selective Norepinephrine-Dopamine Reuptake Inhibitor (**NDRI**) that increases synaptic levels of both **dopamine** and **norepinephrine** [1-3]. Key Clue. The drug name bupropion (Wellbutrin), which uniquely identifies the **NDRI** class on national certification exams [1-3]. Best Answer. C. Dopamine and norepinephrine [2, 3]. Why It Is Correct. Bupropion selectively blocks the presynaptic reuptake transporters for both **dopamine** and **norepinephrine** [1-3]. This dual catecholamine blockade increases synaptic availability of both neurotransmitters, improving energy, motivation, concentration, and mood without modulating serotonin pathways [1, 3, 5]. Why the Other Choices Are Wrong. * **A**: Incorrect because bupropion has no direct affinity or reuptake inhibition for **serotonin** [1, 2]. * **B**: Incorrect because atomoxetine is a selective **norepinephrine** reuptake inhibitor, whereas bupropion inhibits reuptake of both **norepinephrine** and **dopamine** [1, 2, 12]. * **D**: Incorrect because serotonin and norepinephrine reuptake inhibition describes the **SNRI** class, such as venlafaxine or duloxetine [2, 11]. Test-Taking Pearl. Bupropion is the only **NDRI** tested on the boards. Automatically link bupropion to dopamine plus norepinephrine, instantly eliminating any choice containing serotonin [1-3]. Question 1 (Matching Item Excerpt). Question: Match the medication bupropion with its primary involved neurotransmitters (more than one answer may apply): * A. GABA * B. Serotonin * C. Norepinephrine * D. Dopamine Pause. Answer: C and D [1, 3]. Quick Answer. Bupropion acts dual-selectively on **norepinephrine** and **dopamine** [1, 3]. Key Clue. Recognizing bupropion's classification as an **NDRI** [1-3]. Best Answer. C. Norepinephrine and D. Dopamine [1, 3]. Why It Is Correct. Bupropion blocks the reuptake of both **norepinephrine** and **dopamine**, increasing their concentration at the synaptic cleft to enhance focus, energy, and reward processing [1, 3, 5]. Why the Other Choices Are Wrong. * **A**: Incorrect because **GABA** is an inhibitory neurotransmitter targeted by **benzodiazepines**, not bupropion [9, 13]. * **B**: Incorrect because bupropion spares **serotonin**, which prevents serotonergic side effects like **sexual dysfunction** and **diarrhea** [1, 4, 10]. Test-Taking Pearl. Because bupropion boosts both **dopamine** and **norepinephrine**, it can be used off-label for **ADHD** when stimulants are undesirable or contraindicated [3, 11]. Question 2 (Clinical Effect Excerpt). Question: Which clinical effect requires baseline monitoring when initiating bupropion due to its noradrenergic mechanism? * A. Loose bowel movements * B. Elevated blood pressure * C. Galactorrhea * D. Sexual dysfunction Pause. Answer: B [4, 5]. Quick Answer. Noradrenergic reuptake inhibition from bupropion can cause elevated **blood pressure** [4, 5]. Key Clue. The phrase noradrenergic mechanism, which triggers sympathetic activation [5, 8]. Best Answer. B. Elevated blood pressure [4, 5]. Why It Is Correct. By increasing synaptic **norepinephrine**, bupropion stimulates sympathetic pathways, which can cause dose-dependent increases in **blood pressure** and **heart rate** [4, 5]. Baseline and ongoing blood pressure monitoring is required source 4. Why the Other Choices Are Wrong. * **A**: Incorrect because loose bowel movements result from **serotonin** activation on 5-HT receptors in the gastrointestinal tract, common with **SSRIs** [10, 14]. * **C**: Incorrect because **galactorrhea** is caused by **dopamine D2 receptor blockade** in the **tuberoinfundibular pathway**, seen with antipsychotics like risperidone [5, 15, 16]. * **D**: Incorrect because **sexual dysfunction** is caused by **serotonin** 5-HT2 receptor stimulation; bupropion does not cause sexual dysfunction [1, 4, 17]. Test-Taking Pearl. Always check baseline **blood pressure** prior to starting any medication with noradrenergic activity, including bupropion, SNRIs, and psychostimulants [4, 5]. Active Recall Checkpoints. 1. What specific neurotransmitter reuptake pumps does bupropion inhibit [1-3]? 2. Why is bupropion strictly contraindicated in patients with anorexia nervosa or bulimia nervosa [1, 4]? 3. Which vital sign must be assessed at baseline and monitored during bupropion therapy [4, 5]? 4. Why is bupropion preferred when a patient experiences severe sexual dysfunction on an SSRI [1, 4]? 5. What is the required washout period when transitioning between bupropion and an MAOI [1, 4]? Next Study Step. Proceed to **Fitzgerald Chapter 4: Select Neurotransmitters (Serotonin and Histamine)** to master the 5-HT receptor subtypes, gut-brain serotonin dynamics, and H1 receptor blockade side effects like sedation and weight gain [14, 18, 19]. Next. End of this drive.